COMPASS Pathways plc

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that Compass granted equity awards under the Compass Pathways plc 2026 Inducement Plan to nine newly hired non-executive employees. The equity awards were granted on November 2, 2026, and consisted of options to purchase an aggregate of 59,275 shares and restricted share units or, in the case.

Compass Pathways (NASDAQ: CMPS) said it expects to complete its rolling New Drug Application submission for COMP360, its investigational psilocybin treatment for treatment-resistant depression, within two weeks, as the company prepares for a potential U.S. launch in the first half of 2027. Chief Executive Officer Kabir Nath said the company's submission includes two statistically significant Phase

LONDON & JERSEY CITY, N.J.--(BUSINESS WIRE)---- $CMPS #Biotech--Compass Pathways plc (Nasdaq: CMPS), a biotechnology company dedicated to unlocking urgently needed new treatment options in mental health care, announced today that management will attend the Stifel 2026 Healthcare Conference on November 11, 2026 and will participate in a fireside chat at 8:40am ET. A live audio webcast of the fireside chat will be accessible at the following link: https://event.summitcast.com/view/4aFtJriVa3BvDmNqmfSxma/k5kw3HNd3Rg.

COMPASS will complete its New Drug Application submission within two weeks. Interventional psychiatrists surveyed show 90% willingness to prescribe COMP360.